Pfizer And Astellas Pharma Report FDA Grants Priority Review For XTANDI In Non-Metastatic Castration-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted priority review to Pfizer and Astellas Pharma's XTANDI for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. This could potentially expedite the drug's approval process.
August 23, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astellas Pharma's drug XTANDI has been granted priority review by the FDA, which could expedite its approval process.
The FDA's priority review could expedite the approval process for Astellas Pharma's XTANDI, potentially leading to earlier sales and revenue. This is likely to have a positive impact on Astellas Pharma's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's drug XTANDI has been granted priority review by the FDA, which could expedite its approval process.
The FDA's priority review could expedite the approval process for Pfizer's XTANDI, potentially leading to earlier sales and revenue. This is likely to have a positive impact on Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100